Medical Device Definition and Scope in Australia

1. Key takeaways

Australia determines whether a product is a medical device in three steps: first, examine the statutory definition of purpose (the five categories in section 41BD(1)(a)); second, examine whether the principal intended action is achieved by pharmacological, immunological, or metabolic means; third, check whether the article is expressly excluded by a Declaration. The third step must not be skipped, because the exclusion instrument that took effect on 1 January 2026 already lists 16 categories of articles that are not medical devices. Treating the definition question as a single abstract judgement is a common analytical error; in practice each step has its own evidentiary base, its own legal provision, and its own failure mode, and a product can pass the first two steps yet still fall outside the device regime at the third. A written determination that walks through all three steps, with the sources fixed at the time of the judgement, is the most reliable protection when the product’s regulatory identity is later challenged. It also disciplines the internal conversation: engineers, marketers, and regulatory staff are forced to argue from the same statutory text instead of from intuitions about what the product obviously is.

2. Legal basis

1. Therapeutic Goods Act 1989 (Act No. 21, 1990, registration number C2004A03952): the device definition is in section 41BD(1)(a)(i)–(v), with five categories of purpose: the diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of disease; the diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability; the investigation, replacement, or modification of the anatomy or of a physiological or pathological process; control or support of conception; and in vitro examination of specimens derived from the human body.
2. The exclusionary qualification: the proviso in section 41BD(1)(a) — the article must not achieve its principal intended action by pharmacological, immunological, or metabolic means, although it may be assisted by such means.
3. The basis for determining intended purpose: section 41BD(2) — determined according to the labelling, the instructions for use, advertising material, and technical documentation describing the mechanism of action.
4. Expansion and exclusion channels: section 41BD(2A) and (2B) (specifying articles or classes of articles as devices); section 41BD(3) (declaring by legislative instrument that an article or class of articles is not a medical device, while the declared article may still be a therapeutic good).
5. Current exclusion instrument: the Therapeutic Goods (Articles that are Not Medical Devices) Declaration 2023, registration number F2023L01088, current compilation C03, effective on 1 January 2026, with 16 items in Schedule 1.

3. Expert insights

Insight 1: Advertising material is statutory evidence of intended purpose. Section 41BD(2) lists advertising material among the determinants of intended purpose, which means that a single marketing claim can push a product into the device category. At the start of a project we review promotional messaging in parallel with the technical work, so that sales copy does not change the regulatory identity of the product. This is not a theoretical risk: product pages, trade show materials, and social media content are all capable of supplying the statement of purpose on which a classification judgement rests, and none of them are usually drafted with regulatory review in mind. Bringing those materials into scope from the first week costs almost nothing and removes the most common source of late-stage surprises.

Insight 2: The exclusion for the principal intended action is layered. If pharmacological, immunological, or metabolic means achieve the principal action, the article is excluded; if such means merely assist, it is not. For drug-device combination products the key to the determination is distinguishing the primary from the secondary mode of action, not simply observing whether a drug is present. This distinction requires an honest technical analysis of the mechanism, documented before marketing language is written, because the order of operations matters: once a claim hardens in the market, retracing it becomes expensive.

Insight 3: Excluded does not mean unregulated. Section 41BD(3) expressly provides that a declared article may still be a therapeutic good, and it may therefore fall into other therapeutic goods regulatory tracks. Reading the Declaration as a licence to operate freely creates a second compliance gap: the article leaves the device regime yet remains within scope of obligations attached to its therapeutic goods status. The correct reading is narrower — the Declaration answers only the device question, and every other regulatory question must be assessed on its own footing.

4. Practical recommendations

1. At project initiation, issue a written device status determination that works through the five categories of purpose in section 41BD(1)(a) item by item, recording the date of the determination and the version of the sources relied upon.
2. Lock down promotional messaging in parallel: bring labelling, instructions for use, website copy, and trade show materials into a single intended-purpose evidence library and review them together, so that the regulatory and marketing views of the product never diverge.
3. For borderline products, including drug-device combinations, products containing animal-derived or recombinant materials, and software, check the 16-item list in F2023L01088 first before concluding on exclusion, and document that check in the determination file.
4. Whenever the determination changes, re-verify the three parallel lines at the same time: the ARTG entry, advertising compliance, and post-market obligations, because a change in device status ripples through all of them rather than only one.

5. Verification checklist

• □ The five categories of purpose in section 41BD(1)(a) have been worked through item by item, with a written determination
• □ It has been verified whether the principal intended action is achieved by pharmacological, immunological, or metabolic means
• □ The 16-item exclusion list in F2023L01088 (C03, effective 1 January 2026) has been checked
• □ Advertising material has been added to the intended-purpose evidence library and reviewed consistently
• □ Upon any change in the determination, the ARTG, advertising, and post-market lines have all been re-verified

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages TGA inclusion and ARTG listing applications, coordinates conformity assessment evidence, and supports post-market vigilance obligations. Business enquiries: info@grzan.cn